Granules India’s U.S. Facility Inspection Results Analyzed
Granules India recently announced a positive result from a U.S. FDA inspection of its subsidiary, Granules Consumer Health, LLC. The company’s facility passed the inspection with no problems found. This is a really important sign for the company’s business in America.
- FDA inspection completed, zero observations found.
- Second successful inspection after March 2023 audit.
- “No Action Indicated” (NAI) classification previously achieved.
- Facility handles OTC and controlled substances efficiently.
- Supports global operations with U.S. product distribution.
- Demonstrates commitment to quality and regulatory standards.
This inspection was the second time the FDA checked the Granules Consumer Health facility. The first, back in March 2023, didn’t find any issues either – the FDA gave it a “No Action Indicated” rating. This means the FDA didn’t think the company needed to make any changes.
Dr. Krishna Prasad Chigurupati, who leads Granules India, emphasized the company’s commitment to quality and following all rules. He said the company focuses on making sure its products are safe and that they meet the requirements of the FDA.
Granules Consumer Health does a lot of important work. It handles both over-the-counter medicines and medications that need a doctor’s prescription. The company uses tools and processes that Granules India has developed to make sure everything is done right.
Essentially, Granules Consumer Health acts as the first point of contact for Granules India’s OTC products in the United States. It takes advantage of Granules India’s manufacturing expertise, its ability to follow regulations, and how efficiently the company gets its products to customers.
This successful inspection solidifies Granules India’s position as a reliable supplier in the U.S. market.
